PureTech Health Toekomstige groei

Future criteriumcontroles 2/6

De winst van PureTech Health zal naar verwachting dalen met 13% per jaar, terwijl de jaarlijkse omzet naar verwachting zal groeien met 45.2% per jaar. De winst per aandeel zal naar verwachting dalen met 14.1% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting -38.6% zijn.

Belangrijke informatie

-13.0%

Groei van de winst

-14.1%

Groei van de winst per aandeel

Biotechs winstgroei	37.8%
Inkomstengroei	45.2%
Toekomstig rendement op eigen vermogen	-38.6%
Dekking van analisten	Low
Laatst bijgewerkt	27 Sep 2024

Recente toekomstige groei-updates

Recent updates

What You Need To Know About The PureTech Health plc (LON:PRTC) Analyst Downgrade Today

Aug 27

PureTech Health plc Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Apr 18

We're Not So Sure You Should Rely on PureTech Health's (LON:PRTC) Statutory Earnings

Jan 18

Winst- en omzetgroeiprognoses

LSE:PRTC - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	27	-136	-140	-140	3
12/31/2025	14	-122	-175	-135	3
12/31/2024	12	-127	-106	-129	3
6/30/2024	0	-82	-121	-121	N/A
3/31/2024	2	-74	-114	-113	N/A
12/31/2023	3	-66	-106	-106	N/A
9/30/2023	8	-56	-132	-131	N/A
6/30/2023	12	-47	-157	-157	N/A
3/31/2023	14	-49	-169	-168	N/A
12/31/2022	16	-50	-181	-179	N/A
9/30/2022	17	-32	-183	-179	N/A
6/30/2022	19	-14	-185	-180	N/A
3/31/2022	18	-37	-174	-169	N/A
12/31/2021	17	-61	-164	-158	N/A
9/30/2021	14	-127	-156	-150	N/A
6/30/2021	11	-193	-147	-141	N/A
3/31/2021	11	-94	-142	-136	N/A
12/31/2020	12	6	-137	-132	N/A
9/30/2020	12	239	-121	-115	N/A
6/30/2020	12	472	-104	-99	N/A
3/31/2020	11	446	-107	-99	N/A
12/31/2019	10	421	-111	-98	N/A
9/30/2019	15	229	-103	-91	N/A
6/30/2019	20	37	-96	-84	N/A
3/31/2019	20	-3	-87	-78	N/A
12/31/2018	21	-44	-77	-73	N/A
9/30/2018	14	9	-84	-81	N/A
6/30/2018	7	61	-91	-88	N/A
3/31/2018	5	44	N/A	-88	N/A
12/31/2017	3	26	N/A	-89	N/A
9/30/2017	4	-17	N/A	-81	N/A
6/30/2017	5	-61	N/A	-74	N/A
3/31/2017	5	-55	N/A	-66	N/A
12/31/2016	4	-49	N/A	-58	N/A
9/30/2016	3	-54	N/A	-57	N/A
6/30/2016	1	-59	N/A	-55	N/A
3/31/2016	6	-49	N/A	-42	N/A
12/31/2015	12	-39	N/A	-29	N/A
9/30/2015	12	-37	N/A	-19	N/A
6/30/2015	12	-35	N/A	-9	N/A
3/31/2015	7	-38	N/A	-10	N/A
12/31/2014	2	-42	N/A	-11	N/A
12/31/2013	9	-5	N/A	-9	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat PRTC de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat PRTC de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat PRTC de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van PRTC ( 45.2% per jaar) zal naar verwachting sneller groeien dan de markt UK ( 3.6% per jaar).

Hoge groei-inkomsten: De omzet van PRTC ( 45.2% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Er wordt voorspeld dat PRTC binnen 3 jaar verliesgevend zal zijn.

PureTech Health Toekomstige groei

Future criteriumcontroles 2/6

Belangrijke informatie

Recente toekomstige groei-updates

Consensus EPS estimates upgraded to US$0.55 loss

Consensus revenue estimates decrease by 57%

Consensus revenue estimates increase by 973%, EPS downgraded

Consensus revenue estimates fall by 88%

Consensus EPS estimates fall by 29%

Consensus forecasts updated

Recent updates

PureTech Health plc Appoints Lauren White as Chief Financial Officer

Puretech Health plc Presents Research Highlighting Burden of Idiopathic Pulmonary Fibrosis and Use of A Bayesian Stat Analysis for Lyt-100 (Deupirfenidone) At Chest 2024 Annual Meeting

PureTech Health plc Announces KarXT Receives U.S. Food and Drug Administration Approval for the Treatment of Schizophrenia in Adults

Consensus EPS estimates upgraded to US$0.55 loss

Consensus revenue estimates decrease by 57%

New major risk - Revenue and earnings growth

Consensus revenue estimates increase by 973%, EPS downgraded

First half 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Puretech Health plc Appoints Michele Holcomb as Independent Non-Executive Director, Effective September 23, 2024

PureTech Health plc to Report First Half, 2024 Results on Aug 28, 2024

PureTech Health plc Appoints David Wheadon to Its Board of Directors

PureTech Health plc Appoints Raju Kucherlapati as Chair of Board of Directors

PureTech Health plc (LSE:PRTC) announces an Equity Buyback for 33,500,000 shares, representing 12.37% for $100 million.

Seaport Therapeutics Announces Board of Directors Changes and Makes Key Executive Appointments

PureTech Health plc, Annual General Meeting, Jun 13, 2024

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

PureTech Health plc to Report Fiscal Year 2023 Results on Apr 25, 2024

PureTech Health plc Announces Completion of Enrollment in Phase 2b ELEVATE IPF Trial of LYT-100 (Deupirfenidone) in Idiopathic Pulmonary Fibrosis

PureTech Health plc Receives FDA Fast Track Designation for LYT-200 in Head and Neck Cancers

PureTech Health plc Announces Chief Executive Officer Changes

New minor risk - Financial data availability

New major risk - Revenue and earnings growth

Puretech Health plc Presents Data from Phase 1 Trial of Lyt-200 Targeting Galectin-9 in Solid Tumors At the Esmo Immuno-Oncology Congress 2023

Puretech Health plc Announces Topline Results from Its Phase 2A, Randomized, Placebo-Controlled, Proof-Of-Concept Trial of LYT-300

PureTech Presents Data from LYT-100 (Deupirfenidone) Trial in Healthy Older Adults At Chest Annual Meeting

Puretech Announces the Appointment of Robert Lyne as Chief Portfolio Officer

Consensus revenue estimates fall by 88%

First half 2023 earnings: EPS and revenues miss analyst expectations

PureTech Health plc to Report First Half, 2023 Results on Aug 29, 2023

PureTech Health plc Receives Up to $11.4 Million from U.S. Department of Defense to Advance LYT-300 (Oral Allopregnanolone) for Fragile X-Associated Tremor/Ataxia Syndrome

Puretech Health plc Initiates Phase 2A Clinical Trial of Lyt-300 (Oral Allopregnanolone) for the Potential Treatment of Anxiety Disorders

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates fall by 29%

PureTech Health plc to Advance LYT-300 (Oral Allopregnanolone) for the Potential Treatment of Anxiety Disorders and Postpartum Depression

PureTech Health plc Announces Executive Changes

PureTech Health plc Announces Topline Results from the Completed, Multi-Part Phase 1 Trial of LYT-300

PureTech Health plc Presents Data for LYT-200 Targeting Galectin-9 in Preclinical Leukemia Cancer Models at the 64th American Society of Hematology Annual Meeting

PureTech Announces New Therapeutic Candidate, LYT-310, an Oral Form of Cannabidiol (CBD) Leveraging PureTech’s Glyph™ Platform

Nektar Therapeutics (NasdaqGS:NKTR) cancelled the acquisition of PureTech Health plc (LSE:PRTC).

Nektar Therapeutics (NasdaqGS:NKTR) submitted a non-binding proposal to acquire PureTech Health plc (LSE:PRTC).

PureTech Health plc Presents Data for LYT-100 (Deupirfenidone) Supporting Design of Dose-Ranging Trial in Idiopathic Pulmonary Fibrosis (IPF) at European Respiratory Society International Congress 2022

PureTech Health plc Presents Data for LYT-100 (Deupirfenidone) Supporting Design of Dose-Ranging Trial in Idiopathic Pulmonary Fibrosis (IPF) at European Respiratory Society International Congress 2022

Consensus forecasts updated

What You Need To Know About The PureTech Health plc (LON:PRTC) Analyst Downgrade Today

First half 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

PureTech Health plc to Report First Half, 2022 Results on Aug 25, 2022

PureTech Announces Phase 3 Study of Digital Treatment in Children with ADHD Begun by Shionogi in Japan

PureTech Health plc Announces New Akili Data in Lupus

Puretech Health plc Announces the Initiation of A Clinical Study of LYT-100

PureTech Health plc(LSE:PRTC) dropped from FTSE 350 (Ex Investment Companies) Index (GBP)

PureTech Health plc Reports Results from Phase 2 Study of LYT-100-COV in Post-Acute "Long" COVID with Respiratory Complications

PureTech Health plc and Akili Interactive Labs, Inc. Appoints Matt Franklin as President and Chief Operating Officer, Effective June 21, 2022

PureTech Health plc Presents Additional Phase 1 Data for LYT-100

Consensus forecasts updated

Is PureTech Health (LON:PRTC) A Risky Investment?

Full year 2021 earnings: EPS and revenues exceed analyst expectations

PureTech Health plc, Annual General Meeting, Jun 15, 2022

Puretech Founded Entity Vedanta Biosciences Publishes Phase 1A/1B Results for Lead Program Ve303 in Cell Host & Microbe and Highlights Plann Presentations of Phase 2 Ve303 Results

PureTech Health plc Announces Publication of Research from Collaborators Demonstrating PureTech’s Glyph™ Platform Enhances Oral Absorption of Buprenorphine

PureTech Health plc to Report Fiscal Year 2021 Results on Apr 26, 2022

President recently bought UK£51k worth of stock

PureTech Health plc Announces LYT-100 Achieves 50% Reduction in Healthy Older Adults Experiencing GI-Related Adverse Events Compared to Pirfenidone

President recently bought UK£73k worth of stock

Health Check: How Prudently Does PureTech Health (LON:PRTC) Use Debt?

PureTech Health plc Reports on the Key Progress Made Across its Wholly Owned Programs 1 and Founded Entities 2 in 2021

PureTech Health plc's Lymphatic Platform Candidate Human Study

PureTech Announces Publication of New Preclinical Research from Collaborators that Supports Mesenteric Lymphatic Dysfunction as a Potential Cause of and Therapeutic Target for Obesity and Insulin Resistance

Is PureTech Health (LON:PRTC) Using Too Much Debt?

Puretech Health plc Presents LYT-100 Ph1 PK & Tolerability At ERS